7. Other disclosures
7.1 Number of employees
On March 31, 2020, the Sonova Group employed the full time equivalent of 15,184 people (previous year 14,740). They were engaged in the following regions and activities:
By region |
|
31.3.2020 |
|
31.3.2019 |
Switzerland |
|
1,290 |
|
1,224 |
EMEA (excl. Switzerland) |
|
6,866 |
|
6,748 |
Americas |
|
3,550 |
|
3,443 |
Asia/Pacific |
|
3,478 |
|
3,325 |
Total |
|
15,184 |
|
14,740 |
|
|
|
|
|
By activity |
|
|
|
|
Research and development |
|
842 |
|
778 |
Operations |
|
4,618 |
|
4,665 |
Sales and marketing, general and administration |
|
9,724 |
|
9,297 |
Total |
|
15,184 |
|
14,740 |
The average number of employees (full time equivalents) of the Sonova Group for the year was 15,002 (previous year 14,418). Total personnel expenses for the 2019/20 financial year amounted to CHF 1,037.6 million (previous year CHF 1,010.9 million).
7.2 Transactions and relations with members of the Management Board and the Board of Directors
CHF million |
|
2019/20 |
|
2018/19 |
|
2019/20 |
|
2018/19 |
|
2019/20 |
|
2018/19 |
|
|
Management Board |
|
|
|
Board of Directors |
|
|
|
Total |
|
|
Short-term employee benefits |
|
8.6 |
|
7.8 |
|
1.9 |
|
1.8 |
|
10.5 |
|
9.6 |
Post-employment benefits |
|
0.6 |
|
0.7 |
|
|
|
|
|
0.6 |
|
0.7 |
Share based payments |
|
4.8 |
|
4.5 |
|
1.5 |
|
2.0 |
|
6.3 |
|
6.5 |
Total |
|
14.0 |
|
13.1 |
|
3.4 |
|
3.8 |
|
17.4 |
|
16.8 |
The total compensation to the Management Board for the 2019/20 reporting period, as shown above, relates to nine members of the Management Board. The total compensation to the Management Board for the 2018/19 reporting period, as shown above, related to nine members.
The total compensation to the Board of Directors for the 2019/20 reporting period, as shown above, relates to eight active members and one former member (previous year nine members).
Transactions between the Group and the various post-employment benefit plans for the employees of the Group are described in Note 7.3.
Further information in accordance with Swiss law relating to remuneration and ownership of shares and options of the Board of Directors and the Management Board can be found in the compensation report and in the Note 3.6 of the financial statements of Sonova Holding AG.
7.3 Employee benefits
Defined benefit plans
Sonova Group’s retirement plans include defined benefit pension plans in Switzerland, Austria, Canada, Germany and Israel. These plans are both funded and unfunded and governed by local regulations using independent actuarial valuations according to IAS 19. Sonova Group’s major defined benefit plan is located in Switzerland, which in total accounts for CHF 442.9 million or 99.6% (previous year CHF 405.5 million or 99.6%) of Sonova’s defined benefit obligation.
Pension plans in Switzerland
The current pension arrangement for employees in Switzerland is made through a plan governed by the Swiss Federal Occupational Old Age, Survivors and Disability Pension Act (BVG). The plan of Sonova’s Swiss companies is administered by a separate legal foundation, which is funded by regular employer and employee contributions as defined in the pension fund rules. The Swiss pension plan contains a cash balance benefit which is, in essence, contribution-based with certain minimum guarantees. Due to these minimum guarantees, the Swiss plan is treated as a defined benefit plan for the purposes of these IFRS financial statements, although it has many of the characteristics of a defined contribution plan. The plan is invested in a diversified range of assets in accordance with the investment strategy and the common criteria of an asset and liability management. A potential under-funding may be remedied by various measures such as increasing employer and employee contributions or reducing prospective benefits. Above a set insured salary, the savings capital will be split into pension-accumulating and capital-accumulating savings capital. The pension-accumulating savings capital will generate a life-long retirement pension upon retirement. The capital-accumulating savings capital will generate a one-off capital payment upon retirement. An annuity rate of 5.4% to the individual accumulated retirement savings capital was applied for the financial years 2019/20 and 2018/19.
As of March 31, 2020, 1,328 employees (previous year 1,270 employees) and 133 beneficiaries (previous year 123 beneficiaries) are insured under the Swiss plan. The defined benefit obligation has a duration of 13.9 years (previous year 13.7 years).
The results of all defined benefit plans are summarized below:
Amounts recognized in the balance sheet CHF million |
|
31.3.2020 |
|
31.3.2019 |
Present value of funded obligations |
|
(444.5) |
|
(407.0) |
Fair value of plan assets |
|
375.4 |
|
383.2 |
Net present value of funded plans |
|
(69.1) |
|
(23.8) |
Present value of unfunded obligations |
|
(4.4) |
|
(2.2) |
Total liabilities, net |
|
(73.5) |
|
(26.0) |
|
|
|
|
|
Amounts in the balance sheet: |
|
|
|
|
Retirement benefit obligation |
|
(73.5) |
|
(26.0) |
Remeasurements recognized in equity CHF million |
|
2019/20 |
|
2018/19 |
Balance April 1 |
|
32.0 |
|
15.0 |
Actuarial losses/(gains) from |
|
|
|
|
– changes in financial assumptions |
|
6.0 |
|
15.9 |
– changes in experience adjustments |
|
15.2 |
|
3.1 |
Return on plan assets excluding interest income |
|
23.9 |
|
(2.0) |
Balance March 31 |
|
77.1 |
|
32.0 |
Amounts recognized in the income statement CHF million |
|
2019/20 |
|
2018/19 |
Current service cost |
|
27.7 |
|
26.0 |
Participants’ contributions |
|
(11.8) |
|
(11.4) |
Net interest cost |
|
0.2 |
|
0.1 |
Total employee benefit expenses 1) |
|
16.0 |
|
14.7 |
1) The amount recognized in the consolidated income statement 2019/20 has been charged to:
– cost of sales CHF 2.8 million (previous year CHF 2.7 million);
– research and development CHF 5.3 million (previous year 4.9 million);
– sales and marketing CHF 3.4 million (previous year 3.0 million);
– general and administration CHF 4.3 million (previous year CHF 4.0 million);
– financial expenses CHF 0.2 million (previous year CHF 0.1 million).
Movement in the present value of the defined benefit obligations CHF million |
|
2019/20 |
|
2018/19 |
Beginning of the year |
|
409.2 |
|
373.0 |
Interest cost |
|
2.3 |
|
3.2 |
Current service cost |
|
27.7 |
|
26.0 |
Benefits paid, net |
|
(11.4) |
|
(12.0) |
Actuarial loss on obligations |
|
21.2 |
|
19.0 |
Exchange differences |
|
(0.2) |
|
(0.1) |
Present value of obligations at end of period |
|
448.9 |
|
409.2 |
Movement in the fair value of the plan assets CHF million |
|
2019/20 |
|
2018/19 |
Beginning of the year |
|
383.2 |
|
365.6 |
Interest income on plan asset |
|
2.1 |
|
3.1 |
Employer’s contributions paid |
|
13.5 |
|
12.7 |
Participants’ contributions |
|
11.8 |
|
11.4 |
Benefits paid, net |
|
(11.3) |
|
(11.7) |
Return on plan assets excluding interest income |
|
(23.9) |
|
2.0 |
Exchange differences |
|
(0.0) |
|
0.0 |
Fair value of plan assets at end of period |
|
375.4 |
|
383.2 |
The plan assets consist of: |
|
31.3.2020 |
|
31.3.2019 |
Cash |
|
2.4% |
|
2.3% |
Domestic bonds |
|
17.0% |
|
16.4% |
Foreign bonds |
|
8.7% |
|
10.0% |
Domestic equities |
|
12.5% |
|
13.3% |
Foreign equities |
|
28.7% |
|
31.2% |
Real estates |
|
16.3% |
|
15.0% |
Alternative investments |
|
14.4% |
|
11.8% |
All of the plan assets have quoted market prices. The actual return on plan assets amounted to CHF –21.8 million (previous year CHF 5.1 million). The expected employer’s contributions to be paid in the 2020/21 financial year amount to CHF 13.7 million.
Principal actuarial assumptions (weighted average) |
|
2019/20 |
|
2018/19 |
Discount rate |
|
0.45% |
|
0.55% |
Future salary increases |
|
1.00% |
|
1.00% |
Future pension increases |
|
0% |
|
0% |
Fluctuation rate |
|
10% |
|
10% |
Demography |
|
BVG 2015GT |
|
BVG 2015GT |
The following sensitivity analysis shows how the present value of the benefit obligation for the Swiss retirement benefit plan would change if one of the principal actuarial assumptions was changed. For the analysis, changes in the assumptions were considered separately and no interdependencies were taken into account.
Sensitivity analysis – impact on defined benefit obligation CHF million |
|
31.3.2020 |
|
31.3.2019 |
Discount rate |
|
|
|
|
Discount rate +0.25% |
|
(14.2) |
|
(12.9) |
Discount rate –0.25% |
|
16.1 |
|
14.6 |
Salary growth |
|
|
|
|
Salary growth +0.25% |
|
0.8 |
|
0.7 |
Salary growth –0.25% |
|
(0.8) |
|
(0.7) |
Pension growth |
|
|
|
|
Pension growth +0.5% |
|
16.5 |
|
14.8 |
Pension growth –0.5% |
|
(16.5) |
|
(14.8) |
Fluctuation rate |
|
|
|
|
Fluctuation rate +5% |
|
(16.7) |
|
(14.9) |
Fluctuation rate –5% |
|
28.6 |
|
25.4 |
Defined contribution plans
Several of the Group’s entities have a defined contribution plan. The employer’s contributions amounted to CHF 23.5 million in the year ended March 31, 2020 (previous year CHF 21.4 million) and are recognized directly in the income statement.
Accounting policies
Most employees are covered by post-employment plans sponsored by corresponding Group companies in the Sonova Group. Such plans are mainly defined contribution plans (future benefits are determined by reference to the amount of contributions paid) and are generally administered by autonomous pension funds or independent insurance companies. These pension plans are financed through employer and employee contributions. The Group’s contributions to defined contribution plans are charged to the income statement in the year to which they relate.
The Group also has several defined benefit pension plans, both funded and unfunded. Accounting and reporting of these plans are based on annual actuarial valuations. Defined benefit obligations and service costs are assessed using the projected unit credit method, with the cost of providing pensions charged to the income statement so as to spread the regular cost over the service lives of employees participating in these plans. The pension obligation is measured as the present value of the estimated future outflows using interest rates of government securities, which have terms to maturity approximating the terms of the related liability. Service costs from defined benefit plans are charged to the appropriate income statement heading within the operating results.
A single net interest component is calculated by applying the discount rate to the net defined benefit asset or liability. The net interest component is recognized in the income statement in the financial result.
Actuarial gains and losses, resulting from changes in actuarial assumptions and differences between assumptions and actual experiences, are recognized in the period in which they occur in “Other comprehensive income” in equity.
Accounting judgements and estimates
The Sonova Group has various employee benefit plans. Most of its salaried employees are covered by these plans, of which some are defined benefit plans. The present value of the defined benefit obligations at the end of the 2019/20 financial year amounts to CHF 448.9 million (previous year CHF 409.2 million). This includes CHF 442.9 million (previous year CHF 405.5 million) from the Swiss pension plan. With such plans, actuarial assumptions are made for the purpose of estimating future developments, including estimates and assumptions relating to discount rates, and future wage as well as pension trends. Actuaries also use statistical data such as mortality tables and staff turnover rates with a view to determining employee benefit obligations. If these factors change due to a change in economic or market conditions, the subsequent results could deviate considerably from the actuarial reports and calculations. In the medium term, such deviations could have an impact on the equity.
7.4 Equity plans
Equity plans are offered annually to the members of the Board of Directors (BoD), to the members of the Management Board (MB) as well as to other management and senior employees of the Group, entitling them to receive long-term incentives in the form of equity plans free of charge. Equity plans are settled either with Sonova Holding AG shares (equity-settled share-based payment) or for certain US employees with an equivalent amount in cash (cash-settled share-based payment). The amount granted varies depending on the degree of management responsibility held.
In the 2019/20 and 2018/19 financial years, as part of the Executive Equity Award Plan (EEAP) Sonova granted restricted shares, restricted share units (RSUs), performance share units (PSUs), options, and for US employees, share appreciation rights (SARs). Options as well as PSUs granted to the Management Board in 2019/20 and 2018/19 include a performance criterion (for further information refer to compensation report).
For further details on the different instruments granted (especially in regards to performance criteria) to the members of the Management Board, please refer to the compensation report.
The following share-based payment costs have been recognized in the financial years:
CHF million |
|
2019/20 |
|
2018/19 |
Equity-settled share-based payment costs |
|
19.3 |
|
18.8 |
Cash-settled share-based payment costs |
|
0.6 |
|
0.4 |
Total share-based payment costs |
|
19.9 |
|
19.2 |
The following table shows the outstanding options and/or SARs, granted as part of the EEAP 2014 to 2020. All of the equity instruments listed below (except for the non-recurring performance options granted to the COO in 2017/18) vest in 4 equal tranches, annually over a period of 4 years. The non-recurring performance options granted to the CEO vest on April 1, 2023, subject to the achievement of the performance criteria.
Summary of outstanding options and SARs granted until March 31, 2020: |
||||||||||||||
Financial year granted |
|
Instruments granted |
|
First vesting date/ expiry date |
|
Granted |
|
Exercise price (CHF) |
|
Outstanding |
|
Average remaining life (years) |
|
Exercisable |
2013/14 |
|
Options/SARs 1) |
|
1.6.2015 31.1.2021 |
|
242,673 |
|
124.60 |
|
12,606 |
|
0.8 |
|
12,606 |
2014/15 |
|
Options/SARs 2) |
|
1.6.2016 31.1.2022 |
|
308,459 |
|
121.10 |
|
58,864 |
|
1.8 |
|
58,864 |
2015/16 |
|
Options/SARs 3) |
|
1.6.2017 31.1.2023 |
|
298,520 |
|
124.20 |
|
100,288 |
|
2.8 |
|
55,705 |
2016/17 |
|
Options/SARs 4) |
|
1.6.2018 31.1.2024 |
|
378,652 |
|
130.00 |
|
199,599 |
|
3.8 |
|
64,861 |
2017/18 |
|
Options 5) |
|
1.4.2023 30.9.2027 |
|
47,415 |
|
147.85 |
|
47,415 |
|
7.5 |
|
|
2017/18 |
|
Options/SARs 6) |
|
1.6.2019 31.1.2028 |
|
341,943 |
|
147.85 |
|
257,169 |
|
7.8 |
|
44,433 |
2018/19 |
|
Options/SARs 7) |
|
1.6.2020 31.1.2029 |
|
249,760 |
|
182.40 |
|
233,867 |
|
8.8 |
|
|
2019/20 |
|
Options/SARs 8) |
|
1.6.2021 31.1.2030 |
|
208,245 |
|
241.80 |
|
208,245 |
|
9.8 |
|
|
Total |
|
|
|
|
|
2,075,667 |
|
|
|
1'118'053 9) |
|
6.8 |
|
236'469 10) |
Thereof: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-settled |
|
|
|
|
|
1,840,411 |
|
|
|
1,010,087 |
|
|
|
216,608 |
Cash-settled |
|
|
|
|
|
235,256 |
|
|
|
107,966 |
|
|
|
19,861 |
1) Including 107,567 performance options, granted to the CEO and MB members.
2) Including 135,223 performance options, granted to the CEO and MB members.
3) Including 126,206 performance options, granted to the CEO and MB members.
4) Including 147,948 performance options, granted to the CEO and MB members.
5) Non-recurring performance options, granted to the COO (now CEO).
6) Including 150,114 performance options, granted to the CEO and MB members.
7) Including 80,850 performance options, granted to the CEO and MB members.
8) Including 77,574 performance options/SAR, granted to the CEO and MB members.
9) Weighted average exercise price of outstanding options/SARs amounts to CHF 165.60
10) Weighted average exercise price for exercisable options/SARs amounts to CHF 129.48
The fair value of options and/or SARs is calculated at the grant date by using an “Enhanced American Pricing Model”. The expected volatility is based on historical measures. The main valuation assumptions used for the options and/or SARs granted in the current and in the previous financial year are as follows:
Assumptions for valuation at grant date |
|
EEAP 2020 – Management Board Options/SARs |
|
EEAP 2020 Options/SARs |
|
EEAP 2019 Options/SARs |
Valuation date |
|
1.2.2020 |
|
1.2.2020 |
|
1.2.2019 |
Expiry date |
|
31.01.2030 |
|
31.01.2030 |
|
31.1.2029 |
Restriction period |
|
5 years |
|
|
|
|
Share price on grant date |
|
CHF 241.80 |
|
CHF 241.80 |
|
CHF 182.40 |
Exercise price |
|
CHF 241.80 |
|
CHF 241.80 |
|
CHF 182.40 |
Volatility |
|
20.3% |
|
20.3% |
|
21.0% |
Expected dividend yield |
|
1.6% |
|
1.6% |
|
1.8% |
Weighted risk free interest rate |
|
(0.5%) |
|
(0.6%) |
|
(0.2%) |
Weighted average fair value of options/SARs issued |
|
33.34 |
|
31.98 |
|
26.12 |
Options
The exercise price of options is equal to the market price of Sonova Holding AG shares on the SIX Swiss Exchange at grant date. The fair value of the options granted is estimated at grant date and recorded as an expense over the corresponding vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period (including adjustments due to re-assessments of the likely ROCE targets achievements for performance options granted to the CEO and the other members of the MB) to ensure that only a charge for vested amounts occur. Options may be exercised after the vesting date, until their expiry date. If options are exercised, one share per option from the conditional share capital is issued, or treasury shares are used for fulfillment. In the financial year 2019/20 the options granted to the CEO and the members of the MB include a restriction period of 5 years, which was considered in the fair value of the options at grant date.
Changes in outstanding options: |
|
2019/20 |
|
2018/19 |
||||
|
|
Number of options |
|
Weighted average exercise price (CHF) |
|
Number of options |
|
Weighted average exercise price (CHF) |
Outstanding options at April 1 |
|
1,147,865 |
|
142.76 |
|
1,197,443 |
|
130.87 |
Granted 1) |
|
182,407 |
|
241.80 |
|
215,382 |
|
182.40 |
Exercised/sold 2) |
|
(248,711) |
|
125.49 |
|
(232,189) |
|
119.59 |
Forfeited |
|
(71,474) |
|
145.40 |
|
(32,771) |
|
133.06 |
Outstanding options at March 31 |
|
1,010,087 |
|
165.54 |
|
1,147,865 |
|
142.76 |
Exercisable at March 31 |
|
216,608 |
|
129.56 |
|
217,568 |
|
121.64 |
1) 2019/20 includes 72,176 performance options (previous year 80,850 performance options), granted to the CEO and MB members.
2) The total consideration from options exercised amounted to CHF 27.9 million (previous year CHF 27.9 million). The weighted average share price of the options exercised during the year 2019/20 was CHF 223.68 (previous year CHF 176.49).
Share appreciation rights (SARs)
The exercise price of SARs is generally equal to the market price of Sonova Holding AG shares on the SIX Swiss Exchange at grant date. Upon exercise of SARs, an employee shall be paid, an amount in cash equal to the number of shares for which the employee exercised SARs, multiplied by any surplus, of the per share market price at the date of exercise versus the per share exercise price (determined at the date of grant of SARs). The initial fair value of the SARs is in line with the valuation of the options of the respective period and recorded as an expense over the corresponding vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period (including adjustments due to re-assessments of the likely ROCE targets achievements for performance options granted to the members of the MB) to ensure that only a charge for vested amounts occur. Until the liability is settled, it is revalued at each reporting date recognizing changes in fair value in the income statement. The SARs may be sold after the vesting date, until they expire, except for the SARs granted to members of the MB in the financial year 2019/20, which include a restriction period of 5 years.
Changes in outstanding SARs: |
|
2019/20 |
|
2018/19 |
|
||||
|
|
Number of SARs |
|
Weighted average exercise price (CHF) |
|
Number of SARs |
|
Weighted average exercise price (CHF) |
|
Outstanding SARs at April 1 |
|
113,024 |
|
148.27 |
|
102,369 |
|
132.90 |
|
Granted |
|
25,838 |
|
241.80 |
|
34,378 |
|
182.40 |
|
Exercised/sold |
|
(22,168) |
|
128.22 |
|
(8,522) |
|
124.84 |
|
Forfeited |
|
(8,728) |
|
159.37 |
|
(15,201) |
|
135.08 |
|
Outstanding SARs at March 31 1) |
|
107,966 |
|
173.87 |
|
113,024 |
|
148.27 |
|
Exercisable at March 31 2) |
|
19,861 |
|
128.61 |
|
22,423 |
|
123.17 |
|
1) The carrying amount of the liability relating to the SARs at March 31, 2020 is CHF 3.6 million (previous year CHF 4.0 million).
2) The intrinsic value of the SARs exercisable at March 31, 2020 amounts to CHF 0.9 million (previous year CHF 1.7 million).
Performance share units (PSUs)
In 2020, as well as in the previous year, grants made to the members of the Management Board under the EEAP consist of PSUs. The PSUs are measured on relative TSR (rTSR) against the constituents of a recognized index. The fair value of a PSU at grant date was based on a “Monte-Carlo valuation”. PSUs entitle the holder up to two shares per PSU, subject to the achievement of the performance criterion. PSUs granted in 2020 are subject to a restriction period, which was considered in the fair value of the PSU at grant date. Upon vesting of the PSUs, the respective shares are either created out of the conditional share capital or treasury shares are used. The cost of the PSUs granted is expensed over their vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period, including adjustments due to re-assessments of the likely achievements of the rTSR targets for performance of PSUs granted to CEO and the other members of the MB, to ensure that only vested amounts are expensed.
Assumptions for valuation at grant date |
|
PSU 2020 |
|
PSU 2019 |
Valuation date |
|
1.2.2020 |
|
1.2.2019 |
Date of grant |
|
1.2.2020 |
|
1.2.2019 |
Share price on grant date |
|
CHF 241.80 |
|
CHF 182.40 |
Fair value |
|
CHF 266.80 |
|
CHF 224.38 |
End of restriction period |
|
20 months |
|
none |
Performance conditions |
|
Total shareholder return (TSR) |
|
Total shareholder return (TSR) |
TSR performance period |
|
1.2.2020 – 31.3.2023 |
|
1.2.2019 – 31.3.2022 |
TSR comparator group |
|
Swiss Leader Index (SLI) |
|
Swiss Leader Index (SLI) |
Restricted share units (RSUs)
Under the EEAP grants 2014 to 2020, entitled employees have been granted RSUs. The value of an RSU is equal to the market price of Sonova Holding AG shares on the SIX Swiss Exchange on the grant date, adjusted for the fair value of expected dividends, as RSUs are not entitled to dividends. RSUs entitle the holder to one share per RSU after the vesting period. In the case of RSUs granted to the CEO (2014 to 2018) and the other members of the MB (EEAP 2014 to 2017), vesting of these shares is dependent on the fulfillment of the performance criteria which remains the achievement of a pre-defined minimum return on capital employed (ROCE) target. Upon vesting of the RSUs, the respective shares are either created out of the conditional share capital or treasury shares are used. The cost of the RSUs granted is expensed over their vesting period. Assumptions are made regarding the forfeiture rate which is adjusted during the vesting period to ensure that only vested amounts are expensed.
Restricted shares
In addition to the PSUs granted in respect to the EEAP 2020, restricted shares have been granted to the Chairman of the Board of Directors as well as to the other members of the Board of Directors in the financial year 2019/20 and 2018/19. These shares are entitled to dividends and are restricted for a period of 64 months (Chairman), respectively 52 months (other members of the Board of Directors).
The costs for the restricted shares granted to the members of the Board of Directors have been fully expensed in the 2019/20 financial year as these shares have no vesting period.
Changes in outstanding PSUs/RSUs/Restricted shares: |
|
2019/20 |
|
2018/19 |
||||||||||||
|
|
Number of PSUs |
|
Number of RSUs |
|
Number of restricted shares |
|
Total |
|
Number of PSUs |
|
Number of RSUs |
|
Number of restricted shares |
|
Total |
Balance April 1 |
|
25,877 |
|
305,436 |
|
68,574 |
|
399,887 |
|
18,001 |
|
344,990 |
|
72,515 |
|
435,506 |
Granted |
|
8,284 |
|
63,075 |
|
6,157 |
|
77,516 |
|
7,876 |
|
83,326 |
|
10,960 |
|
102,162 |
Released |
|
|
|
(87,669) |
|
(14,473) |
|
(102,142) |
|
|
|
(94,899) |
|
(14,901) |
|
(109,800) |
Forfeited |
|
(2,472) |
|
(21,777) |
|
|
|
(24,249) |
|
|
|
(27,981) |
|
|
|
(27,981) |
Balance March 31 |
|
31,689 |
|
259,065 |
|
60,258 |
|
351,012 |
|
25,877 |
|
305,436 |
|
68,574 |
|
399,887 |
Accounting policies
The Board of Directors of Sonova Holding AG, the Management Board, and certain management and senior employees of other Group companies participate in equity compensation plans. The fair value of all equity compensation awards granted to employees is determined at the grant date and recorded as an expense over the vesting period. The expense for equity compensation awards is charged to the appropriate income statement heading within the operating result and an equivalent increase in equity (for equity-settled compensation) or financial liability (for cash-settled compensation) is recorded. In the case of cash-settled compensation, until the liability is settled, it is revalued at each reporting date, recognizing changes in the fair value in the income statement.
7.5 Events after the balance sheet date
On April 6, 2020, the Group issued a CHF 330 million two year fixed-rate bond with interest rate of 0.55% and maturity date of April 6, 2022. The bond was issued at 100.084% for the first tranche of CHF 260 million and at 100.139% for the second tranche of CHF 70 million.
On April 29, 2020, the Group reached an agreement on terms with three of its relationship banks for a CHF 300 million revolving bridge facility. This will be committed for a period of 12 months after closing, with an option to extend by further 4 months, i.e. a maximum of 16 months.
The global health and economic crisis resulting from the COVID-19 pandemic is severely affecting the hearing care market and with it the Group’s business activities. Audiology stores, the primary consumer channel for hearing care products and services, are either closed or operating with much reduced hours. The Cochlear Implants business is also affected, as the majority of healthcare providers have decided to defer all non-essential surgery. In this context, Sonova has implemented strict cost-reduction programs, which includes government-subsidized work time reductions in a number of countries.
7.6 List of significant companies
Company name |
|
Activity |
|
Domicile (country) |
|
Share/paid-in capital 1) Local currency 1,000 |
|
Shares held |
||
|
|
|
|
|
|
|
|
|
|
|
Switzerland |
|
|
|
|
|
|
|
|
|
|
Sonova Holding AG |
|
A |
|
Stäfa |
|
CHF |
|
3,220 |
|
|
Sonova AG |
|
A, B, C, D |
|
Stäfa |
|
CHF |
|
2,500 |
|
100% |
Advanced Bionics AG |
|
A, B |
|
Stäfa |
|
CHF |
|
4,350 |
|
100% |
Sonova Retail Holding AG |
|
A |
|
Zug |
|
CHF |
|
1,000 |
|
100% |
|
|
|
|
|
|
|
|
|
|
|
EMEA (excluding Switzerland) |
|
|
|
|
|
|
|
|
|
|
Sonova Audiological Care Austria GmbH |
|
B |
|
Wals-Himmelreich (AT) |
|
EUR |
|
450 |
|
100% |
Sonova Retail Belgium NV |
|
B |
|
Groot-Bijgaarden (BE) |
|
EUR |
|
3,686 |
|
100% |
Sonova Deutschland GmbH |
|
B |
|
Fellbach-Oeffingen (DE) |
|
EUR |
|
41 |
|
100% |
Vitakustik GmbH |
|
B |
|
Dortmund (DE) |
|
EUR |
|
500 |
|
100% |
Sonova Retail Deutschland GmbH |
|
B |
|
Dortmund (DE) |
|
EUR |
|
1,000 |
|
100% |
Sonova Retail Denmark ApS |
|
B |
|
Klampenborg (DK) |
|
DKK |
|
1,621 |
|
100% |
Sonova Ibérica S.A.U. |
|
B |
|
Alicante (ES) |
|
EUR |
|
7,000 |
|
100% |
Sonova Audiological Care France SAS |
|
B |
|
Cahors (FR) |
|
EUR |
|
58,800 |
|
100% |
SOD Invest SAS |
|
B |
|
Cahors (FR) |
|
EUR |
|
58,600 |
|
100% |
Sonova France S.A.S. |
|
B |
|
Bron-Lyon (FR) |
|
EUR |
|
1,000 |
|
100% |
Sonova Italia Srl |
|
B |
|
Milan (IT) |
|
EUR |
|
1,040 |
|
100% |
AudioNova Italia |
|
B |
|
Milan (IT) |
|
EUR |
|
1,166 |
|
100% |
Sonova Audiological Care Nederland B.V. |
|
B |
|
Dortrecht (NL) |
|
EUR |
|
19 |
|
100% |
Sonova Audiological Care Polska Sp.z.o.o. |
|
B |
|
Lodz (PL) |
|
PLN |
|
678 |
|
100% |
Boots Hearing Care Ltd. |
|
B |
|
Conwy (UK) |
|
GBP |
|
0 |
2) |
51% |
Sonova UK Ltd. |
|
B |
|
Warrington (UK) |
|
GBP |
|
2,500 |
|
100% |
Sonova Service Center UK Limited |
|
C |
|
Warrington (UK) |
|
GBP |
|
3,150 |
|
100% |
Sonova Israel Ltd. |
|
B |
|
Haifa (IL) |
|
ILS |
|
5,150 |
|
100% |
Activities:
A Holding/Finance: The entity is a holding or finance company.
B Sales: The entity performs sales and marketing activities.
C Production: This entity performs manufacturing for the Group.
D Research: This entity performs research and development activities for the Group.
1) Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.
2) GBP 133
Company name |
|
Activity |
|
Domicile (country) |
|
Share/paid-in capital 1) Local currency 1,000 |
|
Shares held |
||
|
|
|
|
|
|
|
|
|
|
|
Americas |
|
|
|
|
|
|
|
|
|
|
Sonova do Brasil Produtos Audiológicos Ltda. |
|
B |
|
Sao Paulo (BR) |
|
BRL |
|
67,179 |
|
100% |
National Hearing Services Inc. |
|
B |
|
Victoria BC (CA) |
|
CAD |
|
0 |
2) |
100% |
Sonova Canada Inc. |
|
B |
|
Mississauga (CA) |
|
CAD |
|
0 |
2) |
100% |
Connect Hearing Inc. |
|
B |
|
Naperville (US) |
|
USD |
|
0 |
3) |
100% |
Sonova USA, Inc. |
|
B |
|
Plymouth (US) |
|
USD |
|
46,608 |
|
100% |
Advanced Bionics Corp. |
|
A |
|
Valencia (US) |
|
USD |
|
1 |
|
100% |
Advanced Bionics LLC |
|
B, C, D |
|
Valencia (US) |
|
USD |
|
0 |
2) |
100% |
Sonova United States Hearing Instruments, LLC |
|
A |
|
Warrenville (US) |
|
USD |
|
0 |
2) |
100% |
Development Finance Inc. |
|
A |
|
Wilmington (US) |
|
USD |
|
0 |
4) |
100% |
|
|
|
|
|
|
|
|
|
|
|
Asia/Pacific |
|
|
|
|
|
|
|
|
|
|
Hearing Retail Group Pty. Ltd. |
|
B |
|
McMahons Point (AU) |
|
AUD |
|
58,000 |
|
100% |
Sonova Australia Pty Ltd |
|
B |
|
Baulkham Hills (AU) |
|
AUD |
|
10,475 |
|
100% |
Sonova (Shanghai) Co., Ltd. |
|
B |
|
Shanghai (CN) |
|
CNY |
|
20,041 |
|
100% |
Sonova Hearing (Suzhou) Co., Ltd. |
|
C |
|
Suzhou (CN) |
|
CNY |
|
46,249 |
|
100% |
Sonova Japan Co., Ltd. |
|
B |
|
Tokyo (JP) |
|
JPY |
|
10,000 |
|
100% |
Triton Hearing Ltd. |
|
B |
|
Auckland (NZ) |
|
NZD |
|
20,450 |
|
100% |
Sonova Operation Center Vietnam Co., Ltd. |
|
C |
|
Binh Duong (VN) |
|
VND |
|
36,156,000 |
|
100% |
Activities:
A Holding/Finance: The entity is a holding or finance company.
B Sales: The entity performs sales and marketing activities.
C Production: This entity performs manufacturing for the Group.
D Research: This entity performs research and development activities for the Group.
1) Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.
2) Without par value
3) USD 1
4) USD 10
7.7 Other accounting policies
Investments in subsidiaries
Investments in subsidiaries are fully consolidated. These are entities over which Sonova Holding AG directly or indirectly exercises control. Control exists when the Group is exposed, or has rights, to variable returns from its relationship with an entity and has the power to affect those returns. Control is presumed to exist when the parent owns, directly or indirectly through subsidiaries, more than half of the voting power of an entity unless, in exceptional circumstances, it can clearly demonstrate that such ownership does not constitute control. For the consolidated entities, 100% of assets, liabilities, income, and expenses are included. Non-controlling interests in equity and net income or loss are shown separately in the balance sheet and income statement. Changes in the ownership interest of a subsidiary that do not result in a loss of control will be accounted for as an equity transaction. Hence, neither goodwill nor any gains or losses will result.
Group Companies acquired during the year are included in the consolidation from the date on which control over the company transferred to the Group. Group companies divested during the year are excluded from the consolidation as of the date the Group ceased to have control over the company. Intercompany balances and transactions (including unrealized profit on intercompany inventories) are eliminated in full.
Related parties
A party is related to an entity if the party directly or indirectly controls, is controlled by, or is under common control with the entity, has an interest in the entity that gives it significant influence over the entity, has joint control over the entity or is an associate or a joint venture of the entity. In addition, members of the Board of Directors and the Management Board or close members of their families are also considered related parties as well as post-employment plan organizations (pension funds) for the benefit of Sonova employees. No related party exercises control over the Group.
7.8 Effect of new accounting standards
IFRS 16 “Leases”
The standard replaces IAS 17 and sets out new principles for recognition, measurement, presentation and disclosure of leases. The standard provides a single lessee accounting model that requires lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. A lessee is required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments.
The main impact for the Group is on the recognition of new assets and liabilities, primarily for its property and car lease agreements. In addition, the nature of the expenses related to those leases changes as IFRS 16 replaces the straight-line operating lease expenses with a depreciation charge for right-of-use assets and interest expenses on lease liabilities. In the consolidated cash flow statement, repayment of lease liabilities is included in financing activities and no longer in cash flow from operating activities.
The Group has adopted IFRS 16 using the modified retrospective approach. Accordingly, the information presented for the prior period has not been restated and is presented as previously reported under IAS 17.
At transition, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Group’s incremental borrowing rate as at April 1, 2019. Right-of-use assets were measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments recognized immediately before the date of initial application.
The reconciliation of payment obligations from operating leases as at March 31, 2019 for initial recognition as at April 1, 2019 is as follows:
in CHF million |
|
April 1, 2019 |
Operating lease commitments as at March 31, 2019 (IAS 17) |
|
234.6 |
Discounting using the incremental borrowing rate as at April 1, 2019 |
|
(14.0) |
Short-term and low value leases recognized on a straight-line basis as expense |
|
(4.3) |
Adjustments relating to different treatment of contracts and extension and termination options |
|
68.7 |
Lease liabilities as at April 1, 2019 |
|
285.0 |
thereof short-term |
|
63.1 |
thereof long-term |
|
221.9 |
The weighted average incremental borrowing rate as at April 1, 2019 was 1.4%.
Impact on consolidated balance sheet and cash flow statement
The following table summarizes the impact of IFRS 16 on the Group’s consolidated balance sheet at April 1, 2019 and on the consolidated cash flow statement for the financial year 2019/20 for each of the line items affected. Line items that were not affected by the changes have not been included. As a result, the sub-totals and totals disclosed cannot be recalculated from the numbers provided.
Balance sheet |
|
|
|
|
|
|
Assets CHF million |
|
1.4.2019 with IFRS 16 |
|
IFRS 16 effect |
|
31.3.2019 without IFRS 16 |
Right-of-use assets |
|
278.1 |
|
278.1 |
|
|
Total non-current assets |
|
3,258.7 |
|
278.1 |
|
2,980.6 |
Total assets |
|
4,570.6 |
|
278.1 |
|
4,292.5 |
|
|
|
|
|
|
|
Liabilities and equity CHF million |
|
1.4.2019 with IFRS 16 |
|
IFRS 16 effect |
|
31.3.2019 without IFRS 16 |
Current lease liabilities |
|
63.1 |
|
63.1 |
|
|
Short-term provisions |
|
128.2 |
|
(1.0) |
|
129.2 |
Total current liabilities |
|
1,092.2 |
|
62.1 |
|
1,030.1 |
Non-current lease liabilities |
|
221.9 |
|
221.9 |
|
|
Long-term provisions |
|
117.0 |
|
(5.9) |
|
122.9 |
Total non-current liabilities |
|
1,102.3 |
|
216.0 |
|
886.3 |
Total liabilities |
|
2,194.4 |
|
278.1 |
|
1,916.3 |
Total liabilities and equity |
|
4,570.6 |
|
278.1 |
|
4,292.5 |
|
|
|
|
|
|
|
Consolidated cash flow statement |
|
|
|
|
|
|
April 1 to March 31, in CHF million |
|
2019/20 with IFRS 16 |
|
IFRS 16 effect |
|
2019/20 without IFRS 16 |
Income before taxes |
|
502.4 |
|
(1.1) |
|
503.5 |
Depreciation and amortization of tangible and intangible assets and right-of-use assets |
|
200.1 |
|
65.9 |
|
134.2 |
Increase (decrease) in long-term provisions and long-term contract liabilities |
|
22.2 |
|
(0.5) |
|
22.7 |
Financial expense/(income), net |
|
10.0 |
|
4.0 |
|
6.0 |
Cash flow from operating activities |
|
843.3 |
|
68.3 |
|
775.0 |
Repayment of lease liabilities |
|
(64.3) |
|
(64.3) |
|
0.0 |
Interest paid |
|
(5.0) |
|
(4.0) |
|
(1.0) |
Cash flow from financing activities |
|
(550.4) |
|
(68.3) |
|
(482.1) |
As a result of IFRS 16, the cash flow from operating activities for the financial year 2019/20 increased by CHF 68.3 million and the cash flow from financing activities reduced by the same amount.
For the financial year 2019/20 the adoption of IFRS 16 had a minor positive impact of CHF 2.9 million on the EBITA result and a negative impact of CHF 1.1 million on income after taxes.